Key Development
A US federal judge has allowed part of a shareholder lawsuit against Novo Nordisk to proceed. The surviving claim centres on allegations that the company may not have communicated sufficiently clearly about tolerability and dose modification procedures in REDEFINE 1, the pivotal trial evaluating CagriSema for obesity and overweight. The court dismissed several other allegations and has not determined whether Novo Nordisk is legally liable.
REDEFINE 1 reported average weight loss of 20.4% under an estimand reflecting all trial participants, below the 25% expectation previously associated with the programme. Novo Nordisk’s US depositary receipts fell 17.8% following the December 2024 disclosure. Because the protocol allowed flexible dose adjustments, only 57% of participants reached the highest dose, raising questions about tolerability and how investors had interpreted the treatment’s potential.
The broader clinical picture remains more nuanced. Among participants who adhered to treatment, CagriSema delivered average weight loss of 22.7%, while more than 40% achieved weight reduction of at least 25%. Novo Nordisk submitted CagriSema for US regulatory approval in December 2025, confirming that the asset remains central to its future obesity strategy.
Why It Matters
• Legal exposure is expanding from product performance to data communication. Pharmaceutical companies must ensure that investor statements accurately reflect trial design, dose modification rules and the limitations surrounding headline results.
• Tolerability is becoming a defining competitive advantage. In obesity care, maximum weight loss alone is no longer sufficient. Dose persistence, discontinuation rates and treatment experience will shape real world effectiveness and commercial adoption.
• Investor expectations increasingly exceed regulatory thresholds. A clinically successful trial may still be treated as a strategic disappointment when it fails to outperform competitors or meet assumptions already embedded in the company’s valuation.
• CagriSema represents more than a single pipeline asset. It is a test of Novo Nordisk’s ability to move beyond semaglutide and establish differentiated combination therapies as competition from Eli Lilly and emerging obesity developers intensifies.
Healthcare Insight Analysis
The most important strategic issue is not whether CagriSema produces meaningful weight loss. Available evidence indicates that it does. The deeper issue is the gap between scientific objectives, corporate communication and the expectations priced into capital markets.
When a clinical programme becomes central to a company’s growth narrative, details that once appeared technical can become financially material. Flexible dose modification may better reflect clinical practice and improve tolerability. Yet without sufficient explanation, investors may assume that every participant received equivalent exposure to the target dose.
The lawsuit therefore points towards a higher governance standard for pharmaceutical companies managing highly anticipated assets. Clinical development, legal, investor relations and corporate communications teams will need to align earlier on how results are presented, particularly when outcomes vary according to adherence assumptions, statistical estimands or dose escalation strategies.
For Novo Nordisk, reputational consequences may become as important as the ultimate legal outcome. Its obesity care sales reached DKK 82.3 billion in 2025, representing growth of 31% at constant exchange rates. This scale makes sustained confidence in the company’s obesity pipeline increasingly important to its wider investment case.
Market Implications
In the near term, the litigation could increase the risk discount applied to CagriSema and encourage investors to scrutinise efficacy claims from next generation obesity programmes more aggressively.
Over time, competitive assessment is likely to move beyond headline weight loss percentages towards a broader evaluation of tolerability, treatment persistence, dosing flexibility, cardiovascular outcomes and effectiveness outside controlled trials.
The wider industry lesson is clear: in the GLP-1 era, clinical data are not only scientific assets. They are also legal, financial and reputational assets. Companies that manage how evidence is generated, interpreted and communicated will be better positioned to preserve long term value than those focused solely on producing the highest efficacy headline.